Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

Cancer Cell. 2015 Sep 14;28(3):343-56. doi: 10.1016/j.ccell.2015.07.016. Epub 2015 Aug 27.

Abstract

Alterations of IKZF1, encoding the lymphoid transcription factor IKAROS, are a hallmark of high-risk acute lymphoblastic leukemia (ALL), however the role of IKZF1 alterations in ALL pathogenesis is poorly understood. Here, we show that in mouse models of BCR-ABL1 leukemia, Ikzf1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia. Ikzf1 alterations result in acquisition of stem cell-like features, including self-renewal and increased bone marrow stromal adhesion. Retinoid receptor agonists reversed this phenotype, partly by inducing expression of IKZF1, resulting in abrogation of adhesion and self-renewal, cell cycle arrest, and attenuation of proliferation without direct cytotoxicity. Retinoids potentiated the activity of dasatinib in mouse and human BCR-ABL1 ALL, providing an additional therapeutic option in IKZF1-mutated ALL.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle Checkpoints / genetics
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Ikaros Transcription Factor / genetics*
  • Mice
  • Mutation / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Receptors, Retinoic Acid / metabolism
  • Retinoids / metabolism*

Substances

  • Receptors, Retinoic Acid
  • Retinoids
  • Ikaros Transcription Factor
  • Fusion Proteins, bcr-abl

Associated data

  • GEO/GSE54821
  • GEO/GSE68391